About this trial
The investigators aim to study the predictive value of presepsin in ascites in newly admitted patients with chronic liver failure.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patient with ascites and chronic liver failure
no contraindications and technical possibility to perform diagnostic paracentesis
age above 18 years old
informed consent
Disqualifiers
contraindications to paracentesis or technical impossibility to perform paracentesis
absence of informed consent
Trial population
Adult patients admitted with chronic liver failure and ascites. A diagnostic paracentesis will be performed at the day of admission.
Trial design
Cohort
Prospective
Treatments tested in this trial
Determination of presepsin levels in ascites
Diagnostic testA diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
Treatment groups
Trial outcomes
Primary outcomes
Mortality at 6 months
Number of who deceased during admission or during the 180 days after admission divided by the number of patients who were admitted. An analysis will be done to see if the presepsin levels are predictive for this event.
Secondary outcomes
Spontaneous bacterial peritonitis (SBP) rate
The number of patients diagnosed with SBP during admission divided by the total number of patients. An analysis will be done to see if the presepsin levels are predictive for this event.
Hepatic encephalopathy rate
Number of patients diagnosed with hepatic encephalopathy during admission divided by the total number of patients. An analysis will be done to see if the presepsin levels are predictive for this event.
Any infection rate
The number of patients diagnosed with any infection during admission divided by the total number of patients. An analysis will be done to see if the presepsin levels are predictive for this event.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.